Navigation Links
Cumberland Pharmaceuticals Reports First Quarter Financial Results

NASHVILLE, Tenn., May 2, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2013 financial results.

Net Revenue:  For the three months ended March 31, 2013, net revenue was $10.3 million, in line with net revenues from the first quarter of 2012.

Operating Expenses:  Total operating expenses for the three months ended March 31, 2013, were $8.9 million compared to $9.6 million during the prior year period.  This decrease was driven primarily by the realignment of the sales force in late 2012.

Net Income:  Net income attributable to common shareholders for the three months ended March 31, 2013, was $0.9 million, or $0.05 per diluted share, compared to $0.4 million, or $0.02 per diluted share, for the same period in 2012. 

Cash Flow: Operating cash flows for the three months ended March 31, 2013, were $1.7 million, compared to $2.6 million, for the prior year period. 

Balance Sheet:  As of March 31, 2013, Cumberland had $70.2 million in cash and marketable securities, with approximately $51.2 million in cash and equivalents and $19.0 million in marketable securities.  Total assets at March 31, 2013, were $98.3 million.

"Our progress during the first quarter included top line results from three new Caldolor studies and new international partnerships for India and Indonesia," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We were also pleased with the first quarter financial results maintaining revenues from the prior year quarter, while significantly increasing our net income through the efficient management of our expenses."

Product HighlightsAcetadote®

In January 2013, Cumberland initiated shipments of the Company's Authorized Generic version of Acetadote distributed by Perrigo Company. The Authorized Generic resulted from a License and Supply Agreement with Perrigo and a related Settlement Agreement with Paddock Laboratories, LLC and Perrigo Company signed in November 2012.

On March 19, 2013, the United States Patent and Trademark Office issued U.S. Patent number 8,399,445. The claims of this second Acetadote patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose. On April 8, 2013, the new Acetadote patent was listed in the FDA "Orange Book" and it is scheduled to expire in August 2025.


In February 2013, Cumberland announced the top-line results from two registry studies evaluating the safety and efficacy of Caldolor (ibuprofen) Injection administered over a shortened infusion time in treating pain and fever in adult patients. The studies involved 450 patients receiving Caldolor at 34 leading medical centers throughout the United States.

The first of two registry studies was a phase IV multi-center, open-label surveillance clinical study to assess the safety and efficacy of ibuprofen administered intravenously over five to ten minutes to adult patients in the hospital setting with temperature fever (>101 degrees F) and/or pain (visual analog scale (VAS) assessment >3). Eligible patients were enrolled to receive one of two dose strengths (400 mg for treatment of fever, 800 mg for treatment of pain) of intravenous ibuprofen for up to a 24- hour dosing period. One hundred fifty patients from 13 clinical sites were enrolled in this study. Intravenous ibuprofen reduced fever and pain and the shortened infusion time was well tolerated.

The second of two registry studies was a phase IV multi-center, open-label surveillance clinical study to assess the safety of ibuprofen administered intravenously over five to ten minutes to adult hospitalized patients undergoing surgical procedures. Eligible patients were enrolled to receive 800 mg intravenous ibuprofen administered at induction of anesthesia and could continue Caldolor therapy for up to 24 hours. Three hundred patients from 21clinical sites were enrolled in this study. The shortened infusion time was well tolerated.

In February 2013, Cumberland also announced favorable top line results from a pilot clinical study evaluating the safety and analgesic efficacy of Caldolor (ibuprofen) Injection compared to ketorolac injection in treating pain following knee arthroscopy procedures in adult patients. The study was conducted at the Ohio State University Medical Center. The study enrolled fifty-one patients and the results indicate, compared to patients receiving ketorolac, patients receiving intravenous ibuprofen experienced less postoperative pain prior to discharge. Patients receiving Caldolor also needed fewer narcotics and were less likely to require narcotics prior to discharge. This data supports the benefits of using Caldolor in a pre-emptive model of multimodal analgesia.

International Agreements

In January 2013, Cumberland entered into agreements with India's Sandor Medicaids Pvt. Ltd. and Indonesia's PT. SOHO Industri Pharmasi (a SOHO Group company) for the commercialization of Caldolor in those countries. Cumberland also entered into an agreement with GerminMED W.L.L. for the commercialization of Acetadote, Caldolor and Kristalose in the Arabian Peninsula.

Conference Call and WebcastA conference call and live Internet webcast will be held on Thursday, May 2, 2013 at 4:30 p.m. Eastern Time to discuss the Company's first quarter 2013 financial results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 46598348. The live webcast and rebroadcast can be accessed via Cumberland's website at

About Cumberland PharmaceuticalsCumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Company's website at

About AcetadoteAcetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death.  For full prescribing information, visit

About CaldolorCaldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticarial, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit

About KristaloseKristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient.  Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit

Forward-Looking StatementsThis press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets(Unaudited)March 31, 2013December 31, 2012ASSETSCurrent assets:Cash and cash equivalents



54,349,381Marketable securities

18,958,81016,686,136Accounts receivable, net of allowances


5,992,0316,218,355Other current assets

3,892,2393,961,169Total current assets

86,020,25587,232,242Property and equipment, net

1,153,4261,188,914Intangible assets, net

10,403,9749,476,798Other assets

700,095695,777Total assets



98,593,731LIABILITIES AND EQUITYCurrent liabilities:Accounts payable



2,790,554Other current liabilities

4,808,5315,264,806Total current liabilities

8,235,7878,055,360Revolving line of credit

4,359,9514,359,951Other long-term liabilities

652,371611,933Total liabilities

13,248,10913,027,244Commitments and contingenciesEquity:Shareholders' equity:Common stock—no par value; 100,000,000

shares authorized; 18,549,749 and 18,937,107

shares issued and outstanding as of March 31,

2013 and December 31, 2012, respectively

65,818,99567,197,167Retained earnings

19,353,86318,499,154Total shareholders' equity

85,172,85885,696,321Noncontrolling interests

(143,217)(129,834)Total equity

85,029,64185,566,487Total liabilities and equity



98,593,731 CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Income and Comprehensive Income(Unaudited)Three months ended March 31,20132012Net revenues



10,256,212Costs and expenses:Cost of products sold

1,108,635848,550Selling and marketing

3,673,9394,980,553Research and development

1,448,7181,404,022General and administrative


125,050112,047Total costs and expenses

8,932,0819,610,197Operating income

1,326,051646,015Interest income

92,37772,281Interest expense

(17,735)(22,427)Income before income taxes

1,400,693695,869Income tax expense

(559,367)(282,028)Net income

841,326413,841Net loss at subsidiary attributable to noncontrolling interests

13,3839,367Net income attributable to common shareholders



423,208Earnings per share attributable to common shareholders- basic



0.02- diluted



0.02Weighted-average shares outstanding- basic

18,758,38320,007,998- diluted

18,925,16520,234,438Comprehensive income



413,841 CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows(Unaudited)Three months ended March 31,20132012Cash flows from operating activities:Net income



413,841Adjustments to reconcile net income to net cash provided by operating

activities:Depreciation and amortization expense

290,508217,263Deferred tax expense

65,413—Share-based compensation

128,625214,381Excess tax benefit derived from exercise of stock options

(478,698)(191,081)Noncash interest expense

6,0196,019Noncash investment gains (losses)

10,571(8,800)Net changes in assets and liabilities affecting operating activities:Accounts receivable


226,324(230,784)Other current assets and other assets

(8,298)(324,954)Accounts payable and other current liabilities

492,983(282,862)Other long-term liabilities

46,308178,120Net cash provided by operating activities

1,670,6512,610,666Cash flows from investing activities:Additions to property and equipment

(60,911)(32,800)Purchases of marketable securities

(2,970,000)(15,992,822)Proceeds from sale of marketable securities

686,755—Additions to intangible assets

(961,013)(180,787)Net cash used in investment activities

(3,305,169)(16,206,409)Cash flows from financing activities:Net borrowings on line of credit

—250,000Proceeds from exercise of stock options

(41,292)545,601Excess tax benefit derived from exercise of stock options

478,698191,081Repurchase of common shares

(1,942,725)(2,346,524)Net cash used in financing activities

(1,505,319)(1,359,842)Net decrease in cash and cash equivalents

(3,139,837)(14,955,585)Cash and cash equivalents at beginning of period

54,349,38170,599,146Cash and cash equivalents at end of period



55,643,561Supplemental disclosure of cash flow information:Non-cash investing and financing activities:Net change in unpaid additions to intangibles, property and equipment





SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
2. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
3. Cumberland Pharmaceuticals To Announce Second Quarter 2012 Financial Results On August 2, 2012
4. Cumberland Pharmaceuticals Reports Second Quarter 2012 Financial Results
5. Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
6. Cumberland Pharmaceuticals Reports Third Quarter 2012 Financial Results
7. Cumberland Emerging Technologies Expands Life Sciences Center
8. Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
9. Cumberland Pharmaceuticals To Announce 2012 Year End Financial Results On February 28, 2013
10. Cumberland Pharmaceuticals Reports 2012 Annual Financial Results
11. Cumberland Pharmaceuticals To Announce First Quarter 2013 Financial Results On May 2, 2013
Post Your Comments:
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... ) has announced the addition of ... Testing Market: Campylobacter, Cryptosporidium, E. Coli, ... Yersinia" report to their offering. ... announced the addition of the ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... --  Craneware, Inc ., the healthcare market leader ... company will showcase a new version of its ... at the American Society for Health-System Pharmacists (ASHP) ... features are focused on simplifying and streamlining the ... pharmacy charges to ensure compliance and optimal revenue ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- ... of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays ... film for accurate interpretation by the radiologist. The marking utensils are so small, ... Calif., has found a way to alleviate this problem. , He developed the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... Burlington, MA (PRWEB) , ... December 01, 2015 , ... ... the release of Clarity, the latest addition to the devices for sale in the ... technologies, 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - CES, Las Vegas, ... Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, where they will ... Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among ...
Breaking Medicine News(10 mins):